Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) – Pipeline Review, H2 2012

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2012', provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) therapeutic pipeline. This report provides information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ). 'Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ).
- A review of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) pipeline depth and focus of Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) 7
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics under Development by Companies 9
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics – Products under Development by Companies 16
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics Development 18
Shire Plc 18
Green Cross Corporation 19
JCR Pharmaceuticals Co., Ltd. 20
Zacharon Pharmaceuticals, Inc. 21
ArmaGen Technologies, Inc. 22
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 30
JR-032 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Drug For Mucopolysaccharidosis I,II,IIIA,IIIB,IIIC - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Campath-1H + Cyclophosphamide + Busulfan + Allogeneic Stem Cell Transplantation - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
HGT-2310 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
GC1111 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AGT-182 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics – Drug Profile Updates 38
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics – Discontinued Products 39
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics - Dormant Products 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Number of Products Under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H2 2012 7
Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Shire Plc, H2 2012 18
Green Cross Corporation, H2 2012 19
JCR Pharmaceuticals Co., Ltd., H2 2012 20
Zacharon Pharmaceuticals, Inc., H2 2012 21
ArmaGen Technologies, Inc., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 29
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics – Drug Profile Updates 38
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics – Discontinued Products 39
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H2 2012 7
Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28